Asset Details
Do you wish to reserve the book?
Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes
Do you wish to request the book?
Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Identification of Nogo-B as a potential therapeutic target of osteosarcoma via stereochemically selective covalent probes
2025
Overview
Osteosarcoma (OS) has been defined as one of the most intricate and formidable malignant bone tumors, and there has been no significant improvement in targeted therapies for OS over the past 50 years. Therefore, it is crucial to identify new potential drug targets for OS. Here, we have developed a label-free activity-based protein profiling (ABPP) using a stereochemically selective probe from an in-house patrimonial library of covalent small molecule compounds to identify an anti-OS target. Phenotypic screening resulted in the discovery of a selective inhibitor (
S
,
R
)-
4v
that potently suppresses the proliferation of OS 143B cells with an IC
50
value of 0.28 µM. Subsequent label-free ABPP studies identified neurite outgrowth inhibitor B (Nogo-B) as the primary cellular target for (
S
,
R
)-
4v
via a rapid relatively quantitative analysis using its inactive isomer as control. This finding was validated by interaction assays including pull-down, cellular thermal shift assay (CETSA), molecular docking and functional studies. Mechanistic investigations revealed that the apoptotic effect induced by (
S
,
R
)-
4v
was mediated through Nogo-B inhibition of the PI3K/AKT-dependent NF-κB pathway. Altogether, this study presents a novel strategy that couples anti-OS compound screening with target identification and successfully identifies Nogo-B as a potential candidate for targeted OS therapy.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
1-Phosphatidylinositol 3-kinase
/ 13/1
/ 13/2
/ 82
/ 82/58
/ 96
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Biomedical and Life Sciences
/ Bone Neoplasms - drug therapy
/ Carbon
/ Cell Proliferation - drug effects
/ Humans
/ Kinases
/ Molecular Docking Simulation
/ Nogo Proteins - antagonists & inhibitors
/ Proteins
/ Proto-Oncogene Proteins c-akt - metabolism
/ Signal Transduction - drug effects
/ Tumors
